BCT 1902 (Neo-N): A randomised phase II trial evaluating the efficacy of a nivolumab monotherapy lead in window or commencement of nivolumab concurrently with paclitaxel and carboplatin as neoadjuvant therapy in early stage triple negative breast cancers

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 12 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary) ; Carboplatin; Paclitaxel
Indications Early breast cancer; HER2 negative breast cancer; Male breast cancer; Triple negative breast cancer
Focus Therapeutic Use
Acronyms Neo-N

Most Recent Events

22 Oct 2021 Planned number of patients changed from 48 to 108.
05 Aug 2020 Status changed from not yet recruiting to recruiting.
03 Oct 2019 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight